BNP Paribas Financial Markets Lowers Stock Position in Standard BioTools Inc. (NASDAQ:LAB)

BNP Paribas Financial Markets reduced its position in Standard BioTools Inc. (NASDAQ:LAB) by 30.3% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 95,006 shares of the company’s stock after selling 41,231 shares during the quarter. BNP Paribas Financial Markets’ holdings in Standard BioTools were worth $183,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Nisa Investment Advisors LLC boosted its stake in shares of Standard BioTools by 433.8% in the third quarter. Nisa Investment Advisors LLC now owns 18,128 shares of the company’s stock valued at $35,000 after purchasing an additional 14,732 shares during the period. Xponance Inc. acquired a new position in Standard BioTools in the 2nd quarter worth $34,000. Creative Planning purchased a new position in Standard BioTools in the 3rd quarter valued at about $39,000. IQ EQ FUND MANAGEMENT IRELAND Ltd acquired a new stake in shares of Standard BioTools during the second quarter valued at about $39,000. Finally, Algert Global LLC purchased a new stake in shares of Standard BioTools during the second quarter worth about $44,000. Institutional investors and hedge funds own 53.74% of the company’s stock.

Standard BioTools Stock Up 3.3 %

Shares of LAB stock opened at $2.21 on Wednesday. The stock has a 50-day simple moving average of $1.85 and a 200 day simple moving average of $1.95. The stock has a market capitalization of $822.69 million, a P/E ratio of -3.11 and a beta of 1.61. Standard BioTools Inc. has a fifty-two week low of $1.21 and a fifty-two week high of $3.04.

Analyst Upgrades and Downgrades

Separately, TD Cowen dropped their target price on shares of Standard BioTools from $2.75 to $2.50 and set a “buy” rating for the company in a research report on Thursday, October 31st.

Standard BioTools Company Profile

Standard BioTools Inc, together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument.